

AIMS & SCOPE

Global Heart seeks to provide a forum for dialogue and education on matters that relate foremost to the prevention and control of cardiovascular diseases worldwide, with a special focus on countries with middle and lower economies. With the main focus being on prevention, manuscripts should address not only the extent or epidemiology of the problem, but also describe interventions to effectively control and prevent cardiovascular diseases and their antecedent factors. The emphasis should be on approaches that can be applied in settings with limited resources.

GENERAL INFORMATION

©2019 World Heart Federation. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by World Heart Federation, and the following terms and conditions apply to their use:

Photocopying

Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

For information on how to seek permission visit www.elsevier.com/permissions or call: (+44) 18 6584 3830 (UK)/(+1) 215 239 3804 (USA).

Derivative Works

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations (please consult www.elsevier.com/permissions).

Electronic Storage or Usage

Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article (please consult www.elsevier.com/permissions).

Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.

Notice

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Publication Information

Global Heart (ISSN 2211-8160). Volume 10 is currently publishing for 2019. Subscription prices are available upon request from the Publisher or from the Elsevier Customer Service Department nearest you or from this journal's website (www.elsevier.com/globalheart). Further information is available on this journal and other Elsevier products through Elsevier's website (www.elsevier.com). Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by standard mail

(surface within Europe, air delivery outside Europe). Priority rates are available upon request. Claims for missing issues should be made within six months of the date of dispatch.

Author Enquiries

For enquiries relating to the submission of articles (including electronic submission) please visit this journal's homepage at www.journals.elsevier.com/global-heart/ and follow the "Guide for Authors" link. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher. You can track accepted articles at www.elsevier.com/trackarticle. You can also check our Author FAQs at www.elsevier.com/authorFAQ and/or contact Customer Support via support.elsevier.com.

Instructions for Authors

Global Heart has a particular interest in publishing articles addressing epidemiology and health services research (data that utilize updated national or regional demographic health surveys, World Health Organization or Global Burden of Disease data), large clinical disease databases or registries, systematic reviews or meta-analyses on globally-relevant topics, studies that use *validated* instruments to assess health-related quality-of-life in patients with cardiovascular disease from low- and middle-income countries, clinical research (innovative clinical applications, either diagnostic or therapeutic, with preference from low- and middle-income countries, real-world, *effectiveness* clinical trials, particularly from low- and middle-income countries), research methods (innovative methodologic papers, with emphasis on low-cost research methods or novel application of methods in low-resource settings), and papers pertaining to cardiovascular health promotion and policy (quantitative evaluation of health programs, including critical analyses to explain why certain programs failed or why certain policies led to unintended/unanticipated consequences). As a rule, *Global Heart* strongly encourages authors to adhere to CONSORT, STROBE, STARD, and PRISMA guidelines for reporting of clinical trials, observational studies, diagnostic test accuracy papers, and systematic reviews or meta-analyses.

Types of Manuscripts

The following list comprises the sections/types of articles that appear in *Global Heart* and the guidelines for each. Submitted manuscripts should conform to the guidelines of the intended section. The editorial office will make the final decision regarding the section in which an accepted article finally appears.

gSCIENCE [Original Research] Manuscripts falling under this section are reports of *original scientific investigation* in cardiovascular disease prevention and health promotion that have not previously been published and are not being considered for publication elsewhere. Original articles are not to exceed 5000 words, all inclusive. The abstract is 300 words long and structured with the headings **background, objective(s), methods, and conclusions**. We would like you to pay special attention to and discuss in detail the methods (*study design-setting-patients*), and results sections. References should be in Vancouver style. Submission of a manuscript to this journal gives the publisher the right to publish that paper if it is accepted. Manuscripts may be edited to improve clarity and expression. All figures are redrawn by our in-house artists for uniformity. We advise authors to check the figures carefully for accuracy. Reports of the diseases peculiar to developing countries are particularly welcome.

gREVIEW [Reviews or State-of-the-Art Reviews] These reviews should not exceed 7500 words including an unstructured abstract of 150 words. We encourage authors to contact the editorial office with proposals for review articles.

gOPINION [Editorial Comments and Viewpoints] Editorial comments comprise invited articles to accompany important gSCIENCE manuscripts and are 1500 words long. However, viewpoints can be submitted independently; prior consultation with the editors may facilitate preparation of such viewpoints, which are up to 800 words long with no more than 10 references.

gRECS [Expert Consensus Documents, Recommendations, & White Papers] We invite small groups of experts who may help us develop recommendations and guidelines for cardiovascular disease management and prevention, especially pertaining to low- and middle-income countries. This category also includes statements and white papers officially developed by the Scientific Committee of World Heart Federation. In addition, this section also publishes the guidelines and recommendations provided by other major cardiovascular societies simultaneously with other major cardiology journals. There is no page limit established for these manuscripts.

gWATCH [News and Novel Programs] Region-specific cardiovascular programs and news. Items should be no longer than 800 words.

gSOLUTIONS [Innovations and Concepts] The manuscripts are up to 4000 words long with 150-word unstructured abstracts. Such manuscripts highlight resource- and context-specific conceptual advances that may be ready to be translated into clinical and epidemiologic practice.

gHERITAGE [Classics in Global Medicine] With an emphasis on participation of young researchers in mind, this section features the classic studies in cardiovascular epidemiology with the current perspective. These are usually invited submissions, but we do welcome your suggestions. These manuscripts are up to 3500 words long, but we are usually flexible. They contain 150-word unstructured abstracts highlighting the purpose of selection of the classical study for presentation, study findings, and relevance in the current era. All figures will be redone by the in-house artist; therefore, please feel free to send original figures or hand-drawn diagrams. The slides of these classical studies will be made available online. The manuscript should rewrite the original studies and provide the importance in the current era of epidemiological transition in developing/underprivileged nations.

gMAIL [Letters to the Editor] Readers are encouraged to write about any topic that relates to prevention and control of cardiovascular diseases worldwide. Letters should be no longer than 800 words, including 5 references. The correspondence may also address discussion or critique on material previously printed in the journal.

gOVERVIEW [Editor's Page] In every issue, one or more original research manuscripts are highlighted in an accompanying editor's page, the purpose of which is to discuss the importance of the selected manuscript, its potential contributions to global heart health, and to predict future trends. If you feel that your manuscript deserves to be highlighted, please do not hesitate to suggest so in your cover letter at the time of manuscript submission.

Conflict of Interest Statements for Authors

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also <http://www.elsevier.com/conflictsofinterest>.

Global Heart requires full disclosure of all potential conflicts of interest, which must be provided for each and every co-author. The corresponding author is responsible for ensuring all conflicts are included. Investigators should disclose potential conflicts to participants in clinical trials and other studies and should state in the manuscript whether they have done so. *Global Heart* may decide not to publish on the basis of a declared conflict, such as the financial interest of an author in a company (or its competitors) that makes a product discussed in the paper.

Potential Conflicts of Interest Related to Individual Authors' Commitments

When authors submit a manuscript, whether an article or a letter, they are responsible for disclosing all financial and personal relationships that might bias their work. To prevent ambiguity, authors must state explicitly whether potential conflicts do or do not exist.

Orders, Claims, and Journal Enquiries

Please contact the Elsevier Customer Service Department nearest you:

St. Louis Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA; phone: 800 654 2452 [toll free within the USA]; (+1) 314 447 8871 [outside the USA]; fax: (+1) 314 447 8029; e-mail: JournalsCustomerService-usa@elsevier.com

Oxford Elsevier Customer Service Department, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK; phone: (+44) 18 6584 3434; fax: (+44) 18 6584 3970; e-mail: Journals-CustomerServiceEMEA@elsevier.com

Tokyo Elsevier Customer Service Department, 4F Higashi-Azabu, 1-Chome Bldg, 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) 5561 5037; fax: (+81) (3) 5561 5047; e-mail: JournalsCustomerServiceJapan@elsevier.com

Singapore Elsevier Customer Service Department, 3 Killiney Road, #08-01 Winsland House I, Singapore 239519; phone: (+65) 6349 0222; fax: (+65) 6733 1510; e-mail: JournalsCustomerService-APAC@elsevier.com

Advertising Information

Advertising orders and enquires can be sent to: USA, Canada and South America: Elsevier Inc., 230 Park Avenue, Suite 800, New York, NY 10169-0901, USA; phone: (+1) 212 989 5800; Europe and ROW: Elsevier Ltd., 32 Jamestown Road, Camden, London, NW1 7BY, UK; fax: +44 (0) 1865 853 015; e-mail: info@elseviercommercialsales.com.

Funding Body Agreements and Policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit www.elsevier.com/fundingbodies

Global Heart has no page charges

Editorial Office

Julius Center for Health Sciences and Primary Care
University Medical Center Utrecht
Room number 7.103
Internal mail no STR 6.131
P.O. Box 85500
3508 GA UTRECHT the Netherlands

Printed in the Netherlands

The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper)